As­traZeneca to dis­con­tin­ue rare blood can­cer drug in the US

As­traZeneca is re­tir­ing Lu­mox­i­ti, its third-line treat­ment for a rare type of blood can­cer called hairy cell leukemia (HCL), the com­pa­ny con­firmed to End­points News …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER